To identify clinically relevant drugs that could complement the existing NSCLC therapy, we screened a CAD library, containing 72 drugs selected based on their clinical safety profiles and reported ability to inhibit acid sphingomyelinase (Kornhuber et al., 2008, Kornhuber et al., 2010) for cytotoxicity against A549 NSCLC cells. Here, SMPD1 is linked to non-small cell lung carcinoma.